Pfizer Inc. logo

PFE

Pfizer Inc.
NYSE
Healthcare
Drug Manufacturers - General
pfizer.com
$.
$0.20(-0.83%)
Market closedupdated just now
O: $24.15H: $24.24L: $23.74

Market Cap

$136.10B

P/E Ratio

18.23

52W High

$28.75

52W Low

$23.11

Analyst Ratings

No analyst coverage available for PFE.

AI Fair Value Estimate

Get an AI analyst's take on whether PFE looks cheap or expensive — a fair-value range with plain-English reasoning, in one click.

Upgrade to PRO

Insider Trading
50 recent filings

Buys

40

Sells

10

Reported value

$34.60M

50 shown
DateInsiderTypeSharesPriceValueOwned
Jun 15, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Buy23$26.00$598.00-
Jun 9, 2026

DAMICO, JENNIFER B.

SVP & Controller

Sell2,000$25.70$51,400.00-
May 29, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Buy23$26.18$602.14-
May 15, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Buy24$25.33$607.92-
Apr 30, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Buy22$26.70$587.40-
Apr 23, 2026

BLAYLOCK, RONALD E

Director

Buy7,687$26.67$205,000.00-
Apr 23, 2026

GOTTLIEB, SCOTT

Director

Buy7,687$26.67$205,000.00-
Apr 23, 2026

NORA, JOHNSON SUZANNE M

Director

Buy7,687$26.67$205,000.00-
Apr 23, 2026

LITTMAN, DAN R.

Director

Buy7,687$26.67$205,000.00-
Apr 23, 2026

TARAPOREVALA, CYRUS

Director

Buy7,687$26.67$205,000.00-
Apr 23, 2026

ECHEVARRIA, JOSEPH

Director

Buy7,687$26.67$205,000.00-
Apr 23, 2026

NARAYEN, SHANTANU

Director

Buy7,687$26.67$205,000.00-
Apr 23, 2026

QUINCEY, JAMES

Director

Buy7,687$26.67$205,000.00-
Apr 23, 2026

BUCKLEY, MORTIMER J

Director

Buy7,687$26.67$205,000.00-
Apr 23, 2026

DESMOND-HELLMANN, SUSAN

Director

Buy7,687$26.67$205,000.00-
Apr 23, 2026

SMITH, JAMES C

Director

Buy7,687$26.67$205,000.00-
Apr 15, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Buy22$27.19$598.18-
Apr 14, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Buy911$27.11$24,697.21-
Mar 31, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Buy21$28.08$589.68-
Mar 27, 2026

SMITH, JAMES C

Director

Buy1,664$27.04$45,000.00-
Mar 27, 2026

ECHEVARRIA, JOSEPH

Director

Buy1,710$27.04$46,250.00-
Mar 27, 2026

BUCKLEY, MORTIMER J

Director

Buy1,387$27.04$37,499.99-
Mar 27, 2026

QUINCEY, JAMES

Director

Buy1,433$27.04$38,750.00-
Mar 27, 2026

TARAPOREVALA, CYRUS

Director

Buy1,387$27.04$37,499.99-
Mar 27, 2026

NARAYEN, SHANTANU

Director

Buy1,849$27.04$49,999.99-
Mar 13, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Buy1,630$26.58$43,325.40-
Mar 4, 2026

DAMICO, JENNIFER B.

SVP & Controller

Sell826$26.62$21,988.12-
Mar 3, 2026

BAUM, ANDREW

Executive Vice President

Buy303,151$0.00$0.00-
Mar 3, 2026

DAMICO, JENNIFER B.

SVP & Controller

Buy5,408$0.00$0.00-
Mar 3, 2026

DAMICO, JENNIFER B.

SVP & Controller

Buy22,638$0.00$0.00-
Mar 3, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Buy708,666$0.00$0.00-
Mar 3, 2026

BOSHOFF, CHRISTOFFEL

President, R&D

Buy259,844$0.00$0.00-
Mar 3, 2026

DENTON, DAVID M

Chief Financial Officer & EVP

Buy216,537$0.00$0.00-
Mar 3, 2026

LANKLER, DOUGLAS M

Executive Vice President

Buy194,883$0.00$0.00-
Mar 3, 2026

MALIK, AAMIR

Executive Vice President

Buy194,883$0.00$0.00-
Mar 3, 2026

DAMICO, JENNIFER B.

SVP & Controller

Buy16,311$0.00$0.00-
Mar 3, 2026

FONSECA, LIDIA

Executive Vice President

Buy82,284$0.00$0.00-
Mar 3, 2026

MCDERMOTT, MICHAEL

Executive Vice President

Buy151,576$0.00$0.00-
Mar 3, 2026

SAHNI, PAYAL

Executive Vice President

Buy108,268$0.00$0.00-
Mar 3, 2026

DE, GERMAY ALEXANDRE

Executive Vice President

Buy194,883$0.00$0.00-
Feb 27, 2026

DAMICO, JENNIFER B.

SVP & Controller

Sell655$27.65$18,110.75-
Feb 26, 2026

MCDERMOTT, MICHAEL

Executive Vice President

Sell3,503$27.10$94,931.30-
Feb 25, 2026

FONSECA, LIDIA

Executive Vice President

Sell1,058$27.09$28,661.22-
Feb 25, 2026

FONSECA, LIDIA

Executive Vice President

Buy56,888$33.82$1.92M-
Feb 25, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Sell491,626$0.00$0.00-
Feb 25, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Sell467,241$26.92$12.58M-
Feb 25, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Sell8,303$27.09$224,928.27-
Feb 25, 2026

BOURLA, ALBERT

Director, Chairman & CEO

Buy491,626$33.82$16.63M-
Feb 25, 2026

DAMICO, JENNIFER B.

SVP & Controller

Sell17,558$0.00$0.00-
Feb 25, 2026

DAMICO, JENNIFER B.

SVP & Controller

Sell16,687$26.92$449,214.04-

Insider transactions via Alpha Vantage with SEC EDGAR fallback. Data can include grants, planned sales, and administrative filings; this is not investment advice.

More historical data is needed for full RSI, MACD, and Bollinger readings.

AI Technical Interpretation

PRO turns PFE's RSI, MACD, moving averages, and Bollinger Bands into a plain-English read on trend, momentum, and volatility - context, not predictions.

Upgrade to PRO

AI Stock Analysis

Unlock an in-depth, balanced bull/bear breakdown of PFE — catalysts, risks, and a plain-language read on the fundamentals.

Upgrade to PRO

PFE logo
About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Visit pfizer.com

Key Statistics

Open
$24.15
Prev Close
$24.08
Day High
$24.24
Day Low
$23.74
Volume
49.24M
Market Cap
$136.10B
P/E Ratio
18.23
EPS
$1.31
Beta
0.29
Dividend Yield
+7.20%
52W High
$28.75
52W Low
$23.11
Analyst Target